01—Abstract
Summary
Summary of the 10-Q filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) reported a significant increase in revenue for both the three and six months ended March 31, 2024, driven primarily by strong performance in its U.S. Healthcare Solutions segment.
This growth was fueled by higher unit volumes, increased sales of specialty products, and contributions from GLP-1 class drugs and COVID-19 vaccines. Despite increased operating expenses, particularly related to litigation and opioid expenses, the company demonstrated improved gross profit and operating income across its segments. Financially, the company shows robust revenue growth and managed its expenses effectively, leading to increased operating income.
However, investors should note the substantial accrued litigation liability related to opioid settlements, which stands at $5.1 billiona. While the company has a strong liquidity position with substantial cash and cash equivalents and access to credit facilities, the ongoing opioid litigation and the recent cybersecurity event present notable risks and require continued monitoring. The company also continues its share repurchase program and dividend payments, indicating a commitment to returning value to shareholders.
02—Key points
Key Highlights
- Revenue increased by 7.8% to $68.4 billion for the three months ended March 31, 2024, and by 11.4% to $140.7 billion for the six-month period, largely driven by the U.S. Healthcare Solutions segment.
- Gross profit saw a healthy increase of 10.6% and 12.7% for the respective periods, boosted by higher sales and favorable LIFO credits compared to prior year LIFO expenses.
- Operating income increased by 10.9% and 15.2% for the three and six-month periods respectively, reflecting strong performance in both U.S. and International Healthcare Solutions segments.
- The company has accrued $5.1 billion for opioid litigation settlements as of March 31, 2024, with a portion of this liability expected to be paid within the next year.
- Cash and cash equivalents stood at $2.1 billion as of March 31, 2024, with significant availability under credit facilities, indicating a strong liquidity position.
- The company repurchased $436.4 million of its common stock in the first six months of fiscal 2024 and has $2.37 billion remaining under its share repurchase programs.
- Litigation and opioid-related expenses, net, significantly increased in the current period, impacting overall operating expenses, with a notable $214.0 million accrual for ongoing opioid litigation in the first quarter of 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Cencora, Inc. kept $0.01.
- Revenue$68.41B100.0%
- Cost of revenue−$65.88B96.3%
- Gross profit$2.54B3.7%
- Operating costs−$1.98B2.9%
- Operating income$553.3M0.8%
- Interest, other & tax−$132.5M0.2%
- Net income$420.8M0.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed May 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $68.41B$63.46B | +7.8% |
| Cost of Revenue | $65.88B$61.16B | +7.7% |
| Gross Profit | $2.54B$2.30B | +10.6% |
| SG&A Expenses | $1.39B$1.32B | +5.1% |
| Operating Income | $553.26M$560.52M | −1.3% |
| Net Income | $420.77M$435.40M | −3.4% |
| EPS (Basic) | $2.11$2.15 | −1.9% |
| EPS (Diluted) | $2.09$2.13 | −1.9% |
| Shares Outstanding (Basic) | 199.41M202.32M | −1.4% |
| Shares Outstanding (Diluted) | 201.18M204.26M | −1.5% |
05—Questions
Frequently Asked Questions
What is the primary driver of Cencora's revenue growth in this period?
Cencora's revenue growth is primarily driven by its U.S. Healthcare Solutions segment. This growth is attributed to overall market expansion, increased unit volumes, higher sales of specialty products, and significant contributions from GLP-1 class drugs (for diabetes and weight loss) and COVID-19 vaccines.
What is the financial impact of the ongoing opioid litigation on Cencora?
Cencora has accrued a substantial liability of $5.1 billion for opioid litigation settlements as of March 31, 2024. This has led to significantly higher litigation and opioid-related expenses, which impacted operating expenses. The company expects to make substantial payments over the next 14 years.
How is Cencora managing its liquidity and debt?
Cencora maintains a strong liquidity position with $2.1 billion in cash and cash equivalents as of March 31, 2024. The company also has significant availability under its multi-currency revolving credit facility and receivables securitization facility. The company recently issued $500 million in senior notes and is using proceeds to repay maturing debt, demonstrating active debt management.
What is the impact of the recent cybersecurity event?
Cencora experienced a cybersecurity event in February 2024 where data was exfiltrated. While the company incurred costs related to this event, which were recorded in 'Other, net' under restructuring and other expenses, the full financial impact is still being assessed. It also contributed to a delay in collections from certain customers, impacting operating cash flows.
06—Continue